Vision

We are enhancing quality of life through ground-breaking research.

TOPADUR’s vision is to improve patients’ quality of life by providing highly effective and safe drugs for unmet medical conditions.

History

TOPADUR Pharma AG was founded in 2015 by R&D experts with significant experience in pharmaceutical industry.

2021

January

  • Innosuisse grant awarded

February

March

April

May

June

July

August

September

October

November

December

2020

January

February

March

April

May

  • Filing of fourth patent

June

July

  • Dr. Daniel Vassela; new Board Member

August

September

  • Dosing of First Healthy Subjects in Phase 1 Clinical Study of TOP-N53
  • Top100 Swiss Startups 2020

October

November

December

2019

January

February

March

  • Filing of third patent

April

May

  • Innosuisse grant awarded

June

July

August

September

  • Winner of the 6th Dong Sheng Entrepreneurs Cup in Beijing, China
  • Top100 Swiss Startups 2019

October

November

  • Winner of the Young Entrepreneur Award

December

2018

January

February

March

April

May

June

July

August

  • Winner Swiss Innovation Challenge 2017

September

  • Successful Series B Financial Round
  • Top100 Swiss Startups 2018

October

  • Innosuisse grant awarded

November

  • Winner of the prestigious Swiss Economic Award 2018

December

2017

January

  • CTI grant awarded

February

March

April

  • Filing of second patent

May

June

July

August

September

  • Top100 Swiss Startups 2017

October

November

December

2016

January

  • EUROSTARS grant awarded

February

March

  • CTI grant awarded

April

  • Successful Series A Financial Round

May

June

  • CTI Certification

July

August

  • Winner Venture Leaders Life Science 2016

September

  • Top 100 Swiss Startups 2016

October

November

December

  • Winner IMD Startup 2016
2015

January

February

March

  • Foundation Topadur Pharma AG

April

  • Technical Closing Seed funding

May

June

  • Co-Winner Pitching Battle CEO day 2015

July

  • Coaching Acceptance granted by CTI Committee

August

September

October

November

  • Filing of first patent for TOP-N53

December

  • Headquarters / Labs established in Schlieren, Switzerland
  • Finalist Swiss Innovation Challenge 2015
2009-2015

January

February

March

April

May

June

July

August

September

October

November

December

Experimental research phase

2009

January

February

March

April

May

June

July

August

September

October

November

December

  • Foundation TOPADUR GmbH

Leadership

TOPADUR Pharma AG is built on a Leadership Team.

Dr. Reto Naef

Chief Executive Officer | Founder

Reto Naef, founder and Chief Executive Officer of TOPADUR Pharma AG has more than 30 years of experience in pharmaceutical leadership. He is an author of 15 patents and made key contributions to several drugs on the market. Dr. Naef holds a PhD in chemistry from the ETH in Zurich and an MBA from the University of Zurich.

Dr. Hermann Tenor

Chief Scientific Officer

Hermann Tenor is the Chief Scientific Officer and accumulated 24 years of industrial drug discovery and development experience. He was involved in the non-clinical characterization of a first-in-class marketed product. He is co-author on 50 scientific publications. Dr. Tenor holds an MD from the Martin-Luther University Halle Wittenberg.

Christina Attaalla

Chief Financial Officer

Christina Attaalla is the Chief Financial Officer and has 25 years of leading roles in finance, HR and administration heading groups of up to 20 employees and was executive board member for several SMES. She holds a BA in business administration from AKAD Zurich.

Dr. Christian Ludin

Chief Development Officer | Head of Legal

Christian Ludin has more than 20 years of experience in preclinical and clinical drug development. Dr. Ludin is an author and co-inventor of 13 patents and 15 publications and made significant contributions to the development of several preclinical and clinical candidates. He holds a PhD in Chemistry from the University of Freiburg i. Breisgau and an LLM in Law from the Faculty of Law at the University of Zurich.

Dr. Paola Atzei

Chief Project Officer & Communications

Paola Atzei is the Chief Project Officer and Communications. She held several positions as grant and scientific manager at the University of Zurich and Lausanne and worked in a government funding agency in Ireland. Dr. Atzei studied Pharmaceutical Biotechnology and holds a PhD from University College Dublin and a Diploma in Project Management.

Board of Directors

Dr. Reto Naef

Member since 2015

  • Prime Force consultant for scientific affairs, Novartis.                              February 2015 – Now
  • CEO & Founder TOPADUR Pharma.
    2015 – Now
  • Head Research Operations Switzerland, Novartis.                     January 2004 – February 2010

Prof. Dr. Günther Wess

Member since 2015

  • Chairman, Aventis Foundation.
  • Former Director of the Helmholtz Center in Munich till 2018.
  • Cardiovascular diseases, Diabetes and oncology, Former Europe Head Research Höchst, Aventis.

Pascal Brenneisen

Member since 2015

  • Chairman of the Board, Dopavision.
    July 2020 – Now
  • Member Board of Directors, BioCopy. September 2019 – Now
  • Chairman of the Board & Co-Founder, Bottmedical AG.                                       May 2019 – Now

Dr. Dominik Escher

Member since 2018

  • Chairman, CDR-Life.                       January 2017 - Now
  • President of Swiss Biotech Association. April 2013 - Now
  • CEO & Founder,  ESBATech.  September 1998 - 2016

Silvia Scherer

Member since 2020

  • CEO, Hairstetics.
    2016 – Now
  • CEO, Medaesthetis.
    January 2014 – Now
  • Managing Director & General Manager, Anteis. 2003 – 2013

Dr. Daniel L. Vasella

Member since 2020

  • Honorary Chairman of the Board of Directors, Novartis.                                 2013 - Now
  • Chairman of the Board, Novartis.
    April 1999 – February 2013
  • CEO, Novartis.
    May 1996 – February 2010

Dr. Christian Ludin

Secretary of the Board

  • Head of Development & Legal TOPADUR Pharma.                       February 2019 – Now
  • Head of IP & Contracts, Polyphor Ltd.
    January 2002 – February 2018
  • Group Leader, DSM.
    September 1996 – January 2002

Research Partners

TOPADUR Pharma AG in built a research network of world-leader experts from academic institutions to develop its scientific portfolio.

Switzerland

• Prof. Werner
| ETH Zürich
Wound healing diabetic mouse model
• Prof. Scharl
| University Hospital Zurich
Colorectal Cancer
• Prof. Turina
| University Hospital Zurich
Colorectal Cancer
• Prof. Prushy
| University of Zurich
Colorectal Cancer
• Prof. Dengjel
| University of Fribourg
Proteomics
• Prof. Lindenblatt
| University Hospital Zurich
Angiogenesis in wounds of diabetic mice
• Prof. Grimm
| University of Zurich
Retinal cells / Ophthalmology
• Prof. Imanidis
| FHNW University of Applied Sciences
Formulations  development
• Prof. Roska
| Institute of Molecular and Clinical Ophthalmology  Basel
Human retinal circuits / Ophthalmology

France

• Prof. Cracowski
| University Grenoble Alps
Skin perfusion mouse model

Germany

• Prof. Ludwig
| University of Lübeck
Skin fibrosis models

Spain

• Profs. Milara and Cortijo
| University of Valencia
Skin fibrosis models | Rat aortic rings

South Korea

• Profs. Jung and Kwon
| Yonsei University & Seoul National University
Microneedles | Hair Loss